AstraZeneca PLC (AZN)vsPuma Biotechnology Inc (PBYI)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
PBYI
Puma Biotechnology Inc
$7.48
-0.80%
HEALTHCARE · Cap: $382.08M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 25621% more annual revenue ($58.74B vs $228.37M). AZN leads profitability with a 17.4% profit margin vs 13.6%. PBYI appears more attractively valued with a PEG of 0.03. PBYI earns a higher WallStSmart Score of 71/100 (B).
AZN
Buy64
out of 100
Grade: C+
PBYI
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+76.6%
Fair Value
$28.43
Current Price
$7.48
$20.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Growing faster than its price suggests
Every $100 of equity generates 28 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Revenue surging 27.7% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Earnings declined 34.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, Return on Equity, P/E Ratio. Revenue growth of 27.7% demonstrates continued momentum. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a value stock while PBYI is a growth play — different risk/reward profiles.
PBYI carries more volatility with a beta of 1.18 — expect wider price swings.
PBYI is growing revenue faster at 27.7% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
PBYI scores higher overall (71/100 vs 64/100) and 27.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?